Serum Institute of India (SII) gets approval to manufacture Omicron vaccines

One of the major vaccines producing companies of India, the Serum Institute of India has received approval to manufacture vaccines to fight against the omicron variant. This approval has been granted by the Drugs Controller General of India (DCGI). The approval order issued by the Drugs Controller General Of India goes as "With reference to your application, please find herewith the permission to manufacture SARS-CoV-2 rS Protein (COVID-19) recombinant spike protein nanoparticle vaccine (omicron variant) for examination, test, and analysis under the provisions of New Drugs and Clinical Trials Rules, 2019 to manufacture the test batches of the drug/drugs mentioned therein." Serum Institute of India headed by CEO Adar Poonawala, was one of the first drug manufacturers in India to launch a covid vaccine last year by the name ‘Covishield’.